Persistently biased T-cell receptor repertoires in HIV-1-infected combination antiretroviral therapy-treated patients despite sustained suppression of viral replication

Journal of Acquired Immune Deficiency Syndromes

Volumn 34, Issue 2, 2003, Pages 140-154

  Giovannetti, Antonello ^a   Pierdominici, Marina ^a,b   Marziali, Marco ^a   Mazzetta, Francesca ^a   Caprini, Elisabetta ^c   Russo, Giandomenico ^c   Bugarini, Roberto ^d   Bernardi, Maria Livia ^a   Mezzaroma, Ivano ^a   Aiuti, Fernando ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^c LABORATORIO DI PATOLOGIA VASCOLARE   (Italy)

^d University of Rome La Sapienza ^*

Author keywords

HAART; HIV 1; T lymphocytes; T cell receptor

Indexed keywords

ANTIRETROVIRUS AGENT; CD4 ANTIGEN; CD8 ANTIGEN; INDINAVIR; LAMIVUDINE; NELFINAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; T LYMPHOCYTE RECEPTOR; ZIDOVUDINE;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE COURSE; FEMALE; FOLLOW UP; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE DEFICIENCY; MALE; PRIORITY JOURNAL; T LYMPHOCYTE; TREATMENT OUTCOME; VIRUS LOAD; VIRUS REPLICATION;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; FEMALE; GENES, T-CELL RECEPTOR BETA; HIV-1; HLA-DR ANTIGENS; HUMANS; MALE; MIDDLE AGED; T-LYMPHOCYTE SUBSETS; VIREMIA; VIRUS REPLICATION;

EID: 0141889180     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/00126334-200310010-00004     Document Type: Article

References (61)

1. Pantaleo G, Demarest JF, Soudeyns H, et al. Major expansion of CD8+ T cells with a predominant V beta usage during the primary immune response to HIV. Nature. 1994;370:463-467.
2. Wilson JD, Ogg GS, Allen RL, et al. Direct visualization of HIV-1-specific cytotoxic T lymphocytes during primary infection. AIDS. 2000; 14:225-233.
3. Pantaleo G, Demarest JF, Schacker T, et al. The qualitative nature of the primary immune response to HIV infection is a prognosticator of disease progression independent of the initial level of plasma viremia. Proc Natl Acad Sci USA. 1997;94:254-258.
4. Ogg GS, Jin X, Bonhoeffer S, et al. Quantitation of HIV-1-specific cytotoxic T lymphocytes and plasma load of viral RNA. Science. 1998;279: 2103-2106.
5. Phillips RE, Rowland-Jones S, Nixon DF, et al. Human immunodeficiency virus genetic variation that can escape cytotoxic T cell recognition. Nature. 1991;354:453-459.
6. Price DA, Goulder PJ, Klenerman P, et al. Positive selection of HIV-1 cytotoxic T lymphocyte escape variants during primary infection. Proc Natl Acad Sci U S A. 1997;94:1890-1895.
7. Borrow P, Lewicki H, Wei X, et al. Antiviral pressure exerted by HIV-1-specific cytotoxic T lymphocytes (CTLs) during primary infection demonstrated by rapid selection of CTL escape virus. Nat Med. 1997;3:205-211.
8. Goulder PJ, Phillips RE, Colbert RA, et al. Late escape from an immunodominant cytotoxic T-lymphocyte response associated with progression to AIDS. Nat Med. 1997;3:212-217.
9. Pantaleo G, Soudeyns H, Demarest JF, et al. Evidence for rapid disappearance of initially expanded HIV-specific CD8+ T cell clones during primary HIV infection. Proc Natl Acad Sci U S A. 1997;94:9848-9853.
10. Cheynier R, Henrichwark S, Hadida F, et al. HIV and T cell expansion in splenic white pulps is accompanied by infiltration of HIV-specific cytotoxic T lymphocytes. Cell. 1994;78:373-387.
11. + T cells in peripheral blood and lymph nodes from HIV-infected patients. Clin Exp Immunol. 1995;99:182-188.
12. + T cells during the early phase of pediatric human immunodeficiency virus infection: characterization of expanded cell populations by T cell receptor phenotyping. J Infect Dis. 2000;181:107-120.
13. Autran B, Carcelain G, Li TS, et al. Positive effects of combined antiretroviral therapy on CD4+ T cell homeostasis and function in advanced HIV disease. Science. 1997;277:112-116.
14. Domadula G, Zhang H, VanUitert B, et al. Residual HIV-1 RNA in blood plasma of patients taking suppressive highly active antiretroviral therapy. JAMA. 1999;282:1627-1632.
15. Connors M, Kovacs JA, Krevat S, et al. HIV infection induces changes in CD4+ T-cell phenotype and depletions within the CD4+ T-cell repertoire that are not immediately restored by antiviral or immune-based therapies. Nat Med. 1997;3:533-540.
16. + repertoire during antiviral therapy. Nat Med. 1998;4:215-221.
17. + T cell subsets in response to highly active antiretroviral therapy in HIV type 1-infected patients with prior protease inhibitor experience. AIDS Res Hum Retroviruses. 1998;14:561-569.
18. + T-cell repopulation kinetics during highly active antiretroviral therapy. AIDS. 1998;12:F235-F240.
19. + T cell antigen receptor diversity and naive/memory cell phenotype during 9 to 26 months of antiretroviral therapy of HIV-infected patients. AIDS Res Hum Retroviruses. 2000;16:1877-1886.
20. + T-cell expansions in HIV-infected patients on long-term HAART. Clin Exp Immunol. 2001; 126:280-286.
21. King DJ, Gotch FM, Larsson-Sciard EL. T-cell re-population in HIV-infected children on highly active anti-retroviral therapy (HAART). Clin Exp Immunol. 2001;125:447-454.
22. Soudeyns H, Campi G, Rizzardi GP, et al. Initiation of antiretroviral therapy during primary HIV-1 infection induces rapid stabilization of the T-cell receptor beta chain repertoire and reduces the level of T-cell oligoclonality. Blood. 2000;95:1743-1751.
23. Schito AM, Vittinghoff E, Hecht FM, et al. Longitudinal analysis of T-cell receptor gene use by CD8(+) T cells in early human immunodeficiency virus infection in patients receiving highly active antiretroviral therapy. Blood. 2001;97:214-220.
24. Pierdominici M, Giovannetti A, Ensoli F, et al. Changes in CCR5 and CXCR4 expression and beta-chemokine production in HIV-1-infected patients treated with highly active antiretroviral therapy. J Acquir Immune Defic Syndr. 2002;29:122-131.
25. Wei S, Charmley P, Robinson MA, et al. The extent of the human germline T-cell receptor V beta gene segment repertoire. Immunogenetics. 1994;40:27-36.
26. Cottrez F, Auriault C, Capron A, et al. Analysis of the V beta specificity of superantigen activation with a rapid and sensitive method using RT PCR and an automatic DNA analyser. J Immunol Methods. 1994;172:85-94.
27. Giovannetti A, Mazzetta F, Caprini E, et al. Skewed T-cell receptor repertoire, decreased thymic output, and predominance of terminally differentiated T cells in ataxia telangiectasia. Blood. 2002;100:4082-4089.
28. Pierdominici M, Mazzetta F, Caprini E, et al. Biased T cell receptor repertoires in patients with chromosome 22q11.2 deletion syndrome (DiGeorge syndrome/velocardiofacial syndrome). Clin Exp Immunol. 2003; 132:323-331.
29. Thompson JD, Higgins DG, Gibson TJ. CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice. Nucleic Acids Res. 1994;22:4673-4680.
30. Lefranc MP. IMGT, the International ImMunoGeneTics Database. Nucleic Acids Res. 2001;29:207-209.
31. Posnett DN, Kabak S, Hodtsev AS, et al. T-cell antigen receptor V beta subsets are not preferentially deleted in AIDS. AIDS. 1993;7:625-631.
32. + T lymphocytes in HIV-infected individuals following antiretroviral therapy. Curr Opin Immunol. 2001;13:483-488.
33. Imberti L, Sottini A, Bettinardi A, et al. Selective depletion in HIV infection of T cells that bear specific T cell receptor V beta sequences. Science. 1991;254:860-862.
34. + T cells. AIDS. 1993;7:633-638.
35. Laurence J, Hodtsev AS, Posnett DN. Superantigen implicated in dependence of HIV-1 replication in T cells on TCR V beta expression. Nature. 1992;358:255-259.
36. Garcia S, Dadaglio G, Cilote V, et al. Evidence for an in vivo superantigenic activity in human immunodeficiency virus-infected individuals. Blood. 1996;88:2151-2161.
37. Eick A, Larned J, Jason J. Effects of HIV-1 peptides on T-cell receptor variable beta chain families. Hum Immunol. 2000;61:993-1000.
38. Soudeyns H, Rebai N, Pantaleo GP, et al. The T cell receptor V beta repertoire in HIV-1 infection and disease. Semin Immunol. 1993;5:175-185.
39. + T cells of human immunodeficiency virus-infected infants. Eur J Immunol. 1993;23:2041-2044.
40. + T lymphocytes and functional integrity of T-cell repertoire during acute HIV syndrome. AIDS. 1995;9:547-553.
41. Westby M, Vaughan AN, Balotta C, et al. Low CD4 counts rather than superantigenic-like effects account for differences in expressed T-cell receptor (TCR) repertoires between HIV-1 seropositive long-term non-progressors and individuals with progressive disease. Br J Haematol. 1998;102:1187-1196.
42. + T-lymphocytes in HIV-infected individuals. Hum Immunol. 2002;63:51-60.
43. + T cells in individuals receiving highly active antiretroviral therapy (HAART). J Immunol. 1999;162:1780-1788.
44. + T cells in HIV-infected progressors and long-term nonprogressors. J Immunol. 2000; 165:1082-1092.
45. Sharkey ME, Teo I, Greenough T, et al. Persistence of episomal HIV-1 infection intermediates in patients on highly active anti-retroviral therapy. Nat Med. 2000;6:76-81.
46. Zhang L, Ramratnam B, Tenner-Racz K, et al. Quantifying residual HIV-1 replication in patients receiving combination antiretroviral therapy. N Engl J Med. 1999;340:1605-1613.
47. Furtado MR, Callaway DS, Phair JP, et al. Persistence of HIV-1 transcription in peripheral-blood mononuclear cells in patients receiving potent antiretroviral therapy. N Engl J Med. 1999;340:1614-1622.
48. Hazenberg MD, Stuart JW, Otto SA, et al. T-cell division in human immunodeficiency virus (HIV)-1 infection is mainly due to immune activation: a longitudinal analysis in patients before and during highly active antiretroviral therapy (HAART). Blood. 2000;95:249-255.
49. + T cell response after virologic failure of protease inhibitor-based regimens in patients with human immunodeficiency virus infection. J Infect Dis. 2000;181:946-953.
50. + naive T cells following triple-drug therapy for HIV type 1 infection. AIDS Res Hum Retroviruses. 1999;15:435-443.
51. + T-cell turnover in HIV-1 infection: a paradigm revisited. Immunol Today. 1998;19: 44-48.
52. + T cells go out of stock. Nat Immunol. 2000; 1:285-289.
53. Isgrò A, Aiuti A, Mezzaroma I, et al. Improvement of interleukin 2 production, clonogenic capability and restoration of stromal cell function in human immunodeficiency virus-type-1 patients after highly active antiretroviral therapy. Br J Haematol. 2002;118:864-874.
54. Isgrò A, Aiuti F, Mezzaroma I, et al. Interleukin 7 production by bone marrow-derived stromal cells in HIV-1-infected patients during highly active antiretroviral therapy. AIDS. 2002;16:2231-2232.
55. Napolitano LA, Grant RM, Deeks SG, et al. Increased production of IL-7 accompanies HIV-1-mediated T-cell depletion: implications for T-cell homeostasis. Nat Med. 2001;7:73-79.
56. Mussini C, Pinti M, Borghi V, et al. Features of " CD4-exploders," HIV-positive patients with an optimal immune reconstitution after potent antiretroviral therapy. AIDS. 2002;16:1609-1616.
57. Ledergerber B, Telenti A, Egger M. Risk of HIV related Kaposi's sarcoma and non-Hodgkin's lymphoma with potent antiretroviral therapy: prospective cohort study. Swiss HIV Cohort Study. BMJ. 1999;319:23-24.
58. Matthews GV, Bower M, Mandalia S, et al. Changes in acquired immunodeficiency syndrome-related lymphoma since the introduction of highly active antiretroviral therapy. Blood. 2000;96:2730-2734.
59. Gerard L, Galicier L, Maillard A, et al. Systemic non-Hodgkin lymphoma in HIV-infected patients with effective suppression of HIV replication: persistent occurrence but improved survival. J Acquir Immune Defic Syndr. 2002;30:478-484.
60. Przybylski GK, Goldman J, Ng VL, et al. Evidence for early B-cell activation preceding the development of Epstein-Barr virus-negative acquired immunodeficiency syndrome-related lymphoma. Blood. 1996;88: 4620-4629.
61. Centers for Disease Control and Prevention. 1993 Revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR Morb Mortal Wkly Rep. 1993;41:1-19.